title: Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
authors.affiliation: Neurology A, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.|Neuro-oncology and Neuroinflammation Team, Lyon Neurosciences Research Center, Lyon, France.|Claude Bernard University Lyon 1, Lyon, France.|University of Lyon, Lyon, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Marignier
authors.affiliation: Neurology A, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Durand-Dubief
authors.affiliation: Laboratory of Neuroimmunology, Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland.
authors.forename: Renaud
authors.initials: R
authors.lastname: du Pasquier
authors.affiliation: Neurology A, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.|Neuro-oncology and Neuroinflammation Team, Lyon Neurosciences Research Center, Lyon, France.|Claude Bernard University Lyon 1, Lyon, France.|University of Lyon, Lyon, France.
authors.forename: Sandra
authors.initials: S
authors.lastname: Vukusic
mesh_terms: D000068876:Fingolimod Hydrochloride; D006801:Humans; D007155:Immunologic Factors; D007968:Leukoencephalopathy, Progressive Multifocal; D009103:Multiple Sclerosis; D020529:Multiple Sclerosis, Relapsing-Remitting; D000069442:Natalizumab; D000069283:Rituximab
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab; D000069283:Rituximab; D000068876:Fingolimod Hydrochloride